Clinical Trial ProgressCYB003 pivotal program scaling globally, with ongoing preparations in commercial-scale manufacturing and clinic partnerships advancing in parallel, setting up CYB003 as a potential first-in-class intermittent treatment for major depressive disorder.
Funding And Financial PositionContinued operational de-risking through commercial-scale manufacturing, clinic-network partnerships, and a US$500 million convertible debenture facility extends runway beyond 2026.
Regulatory ApprovalsCYB003 Phase 3 EMBRACE trial regulatory clearances underscore scale and speed of execution, with approvals secured in the U.K. and selected EU territories.